Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jun 1;73(11):1054-8.
doi: 10.1016/j.biopsych.2012.12.009. Epub 2013 Jan 16.

D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia

Affiliations
Randomized Controlled Trial

D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia

Jasper A J Smits et al. Biol Psychiatry. .

Abstract

Background: Whereas some studies have shown clear evidence for an augmentation effect of D-cycloserine (DCS) on exposure therapy for anxiety disorders, other studies have shown weak effects or no effect at all. Some preclinical data suggest that the DCS augmentation effect is moderated by the success of extinction learning. Therefore, we conducted a reanalysis of existing data to examine whether the effects of DCS on clinical outcome would vary as a function of response to the exposure session (i.e., exposure success).

Methods: In a clinical trial, patients with height phobia received two sessions involving 30 minutes of virtual reality exposure therapy and were randomly assigned to a pill placebo (n = 14) or 50 mg of DCS (n = 15) immediately after each session.

Results: Mixed-effects regression analysis showed that the effects of DCS administration on clinical improvement was moderated by the level of fear experienced just before concluding exposure sessions. Patients receiving DCS exhibited significantly greater improvement in symptoms relative to patients who received placebo when fear was low at the end of the exposure. In contrast, when end fear was still elevated, patients receiving DCS improved less compared with those receiving placebo.

Conclusions: D-cycloserine appears to enhance the benefits of exposure treatment when applied after a successful session, but it seems to have detrimental effects when administered after inadequate/unsuccessful exposure sessions.

Trial registration: ClinicalTrials.gov NCT01102803.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CGI-I outcome effects of the interaction between drug condition and exposure adequacy as assessed by end fear scores. Note. CGI-I is the Clinical Global Impressions Improvement scale that uses a 7-point scale, with lower scores indicating greater improvement 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse). End Fear is the fear rating provided just prior to concluding the exposure exercises. Fear was rated 0-100 scale (0 = no fear; 50 = moderate fear; 100 = extreme fear or panic), and thus 0 indicates exposure success and higher ratings indicate less exposure success.

References

    1. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63:1118–1126. - PubMed
    1. Hofmann SG, Smits JA, Asnaani A, Gutner CA, Otto MW. Cognitive enhancers for anxiety disorders. Pharmacol Biochem Behav. 2011;99:275–284. - PMC - PubMed
    1. Woods AM, Bouton ME. D-cycloserine facilitates extinction but does not eliminate renewal of the conditioned emotional response. Behavioral neuroscience. 2006;120:1159–1162. - PubMed
    1. Weber M, Hart J, Richardson R. Effects of D-cycloserine on extinction of learned fear to an olfactory cue. Neurobiol Learn Mem. 2007;87:476–482. - PubMed
    1. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW, et al. A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res. 2012 - PubMed

Publication types

Associated data